Home › Ovarian Epithelial Carcinoma › Alabama › Birmingham
Ovarian Epithelial Carcinoma clinical trials in Birmingham, AL
4 studies for Ovarian Epithelial Carcinoma are looking for participants at sites in and around Birmingham (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
RecruitingPhase 2
- University of Alabama at Birmingham (UAB) Hospital /ID# 274793, Birmingham
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
RecruitingObservational study
- University of Alabama at Birmingham, Birmingham
AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer
RecruitingPhase 3
- Research Site, Birmingham
Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer
Recruiting
- University of Alabama at Birmingham, Birmingham
Ovarian Epithelial Carcinoma trials in other cities
- Durham, NC8 studies
- Boston, MA8 studies
- San Diego, CA7 studies
- New York City, NY7 studies
- Chicago, IL7 studies
- Baltimore, MD6 studies
- Cleveland, OH6 studies
- Philadelphia, PA6 studies
- Houston, TX6 studies
- Portland, OR5 studies
- Salt Lake City, UT5 studies
- Minneapolis, MN5 studies
Other studies in Birmingham
- Cancer (all types)31 studies
- Breast Cancer24 studies
- Ovarian Cancer23 studies
- Obesity23 studies
- Non-Small Cell Lung Cancer22 studies
- Acute Myeloid Leukemia21 studies
- Multiple Myeloma18 studies
- COPD17 studies
- Cardiovascular Disease17 studies
- Type 2 Diabetes16 studies
- Endometrial Cancer16 studies
- Overweight16 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.